Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 168]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Aileron Therapeutics, Inc. - Market capitalization
Aileron Therapeutics, Inc.
ALRN

$76.91 M
Marketcap
$3.55
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Categories

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

marketcap